StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$18.32−0.35 (-1.87%)

Close on Nov 17, 2026Market cap $3.16BP/E 8.3Yield –

Acadia Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Acadia Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $160.32M, down 14.7% year over year. For fiscal 2025 it was $109.84M, down 30.4% from the year before. The highest annual figure on record is $157.72M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$109.84M-30.4%
FY2024Dec 31, 2024$157.72M+844.3%
FY2023Dec 31, 2023$16.70M–
FY2022Dec 31, 2022-$114.04M–
FY2021Dec 31, 2021-$125.66M–
FY2020Dec 31, 2020-$136.17M–
FY2019Dec 31, 2019-$151.13M–
FY2018Dec 31, 2018-$167.47M–
FY2017Dec 31, 2017-$217.76M–
FY2016Dec 31, 2016-$208.41M–
FY2015Dec 31, 2015-$121.80M–
FY2014Dec 31, 2014-$66.43M–
FY2013Dec 31, 2013-$31.77M–
FY2012Dec 31, 2012-$21.63M–
FY2011Dec 31, 2011-$19.90M–
FY2010Dec 31, 2010-$10.70M–
FY2009Dec 31, 2009-$13.73M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$100.78M+57.6%
Q1 FY2026Mar 31, 2026$33.98M+67.2%
Q4 FY2025Dec 31, 2025-$48.73M-220.7%
Q3 FY2025Sep 30, 2025$74.29M+17.5%
Q2 FY2025Jun 30, 2025$63.96M+155.7%
Q1 FY2025Mar 31, 2025$20.32M-30.1%
Q4 FY2024Dec 31, 2024$40.38M-52.7%
Q3 FY2024Sep 30, 2024$63.25M–
Q2 FY2024Jun 30, 2024$25.01M+205.0%
Q1 FY2024Mar 31, 2024$29.08M–
Q4 FY2023Dec 31, 2023$85.39M–
Q3 FY2023Sep 30, 2023-$58.96M–
Q2 FY2023Jun 30, 2023$8.20M–
Q1 FY2023Mar 31, 2023-$17.93M–
Q4 FY2022Dec 31, 2022-$23.85M–
Q3 FY2022Sep 30, 2022-$727.00K–
Q2 FY2022Jun 30, 2022-$13.13M–
Q1 FY2022Mar 31, 2022-$76.33M–
Q4 FY2021Dec 31, 2021-$23.12M–
Q3 FY2021Sep 30, 2021-$17.06M–
Q2 FY2021Jun 30, 2021-$25.33M–
Q1 FY2021Mar 31, 2021-$60.15M–
Q4 FY2020Dec 31, 2020-$27.49M–
Q3 FY2020Sep 30, 2020-$22.79M–
Q2 FY2020Jun 30, 2020-$36.88M–
Q1 FY2020Mar 31, 2020-$49.00M–
Q4 FY2019Dec 31, 2019-$29.71M–
Q3 FY2019Sep 30, 2019-$18.85M–
Q2 FY2019Jun 30, 2019-$38.40M–
Q1 FY2019Mar 31, 2019-$64.18M–
Q4 FY2018Dec 31, 2018-$39.08M–
Q3 FY2018Sep 30, 2018-$42.28M–
Q2 FY2018Jun 30, 2018-$40.88M–
Q1 FY2018Mar 31, 2018-$45.24M–
Q4 FY2017Dec 31, 2017-$29.90M–
Q3 FY2017Sep 30, 2017-$58.40M–
Q2 FY2017Jun 30, 2017-$58.90M–
Q1 FY2017Mar 31, 2017-$70.56M–
Q4 FY2016Dec 31, 2016-$61.19M–
Q3 FY2016Sep 30, 2016-$49.26M–

More Acadia Pharmaceuticals figures

See a number that looks wrong?